Update shared on16 Sep 2025
Fair value Decreased 3.19%Lantheus Holdings’ consensus price target has been revised downward to $86.64, primarily due to lowered Pylarify pricing assumptions, ongoing underperformance and heightened competition, partially offset by longer-term optimism for emerging products.
Analyst Commentary
- Lowered Pylarify pricing assumptions for 2025-2026 and increased OpEx estimates are expected to reduce near-term EPS and drive price target cuts.
- Ongoing uncertainty and deceleration in Pylarify's performance, following multiple quarters of missed expectations, have led to a cautious near- to mid-term outlook and multiple compression.
- Intensified competitive pricing from Blue Earth is putting additional pressure on Pylarify's business and impacting company guidance, though domestic volumes remain slightly up year-over-year.
- Despite negative sentiment around Pylarify, some analysts remain encouraged by longer-term royalty opportunities from products like Flyrcado and Pylclari.
- Analysts note the potential for recovery in Pylarify pricing and business trends post-2026, contingent on new formulation approval and stabilization of competitive dynamics.
What's in the News
- Lantheus Holdings faces a class action lawsuit alleging false statements regarding Pylarify’s growth prospects and the company’s competitive positioning, with claims of significant stock price declines following revised projections and disappointing sales updates (Robbins Geller Rudman & Dowd LLP, 11 Sep 2025).
- The company has substantially lowered its full-year 2025 revenue guidance to $1.475–$1.51 billion from the previous range of $1.55–$1.585 billion, reflecting weaker than expected Pylarify sales (Corporate Guidance, 6 Aug 2025).
- Lantheus announced the FDA acceptance of a New Drug Application for a next-generation F 18 PSMA imaging agent through affiliate Aphelion, expected to broaden patient access and boost manufacturing scale, with a decision date in March 2026 (Product-Related Announcement, 6 Aug 2025).
- The Board authorized a share repurchase program up to $400 million valid through December 2027; as of June 2025, the company has already completed $199.94 million in buybacks (Buyback Announcements, 31 Jul & 6 Aug 2025).
- Lantheus joined Pfizer and Lumina Pharmaceuticals in the FIBRE Consortium, aiming to develop imaging biomarkers for fibrotic diseases and accelerate the creation of new therapies using advanced PET and MRI technologies (Strategic Alliances, 20 Jun 2025).
Valuation Changes
Summary of Valuation Changes for Lantheus Holdings
- The Consensus Analyst Price Target has fallen slightly from $89.50 to $86.64.
- The Future P/E for Lantheus Holdings remained effectively unchanged, moving only marginally from 16.80x to 16.51x.
- The Net Profit Margin for Lantheus Holdings remained effectively unchanged, moving only marginally from 23.37% to 23.03%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.